Helixgate https://validator.w3.org/feed/docs/rss2.html Home STAT+: Up and Down the Ladder: The latest comings and goings FDA awards priority vouchers to 3 undisclosed companies for investigational psychedelics Avalyn plots $182M IPO; WHO prequalifies Novartis’ malaria drug Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics Exclusive: UC Berkeley startup bets on jumping genes for GLP-1 gene therapy International childhood vaccine campaign grows STAT+: Sanofi MS drug gets positive review in Europe following FDA BioSpace elevates journalism as biopharma evolves in the Trump era A CAR-T biotech’s dramatic turnaround, and drugmakers’ tactics to drive more scripts AI in Oncology Takes Off, Tackling HIV and Liver Disease, Pharma’s Recent Gains Daiichi Sankyo shares slip after delaying annual earnings report Sanofi’s tolebrutinib gets CHMP backing for certain MS patients despite FDA rejection Regeneron finally joins Trump’s drug pricing push while notching landmark approval Pfizer’s strategy chief Andrew Baum steps down; Helus Pharma swaps out CEO after two months Daiichi Sankyo postpones annual results, stock dips Psychedelics get a boost from the White House Opinion: Prasad’s FDA exit good for rare diseases but new CBER head must repair eroded trust Enabling In Vivo Lentiviral Therapies: Manufacturing Strategies to Improve Purity, Scalability, and Clinical Readiness STAT+: Trump celebrates closing first round of drug pricing deals, promises more ahead FDA approves Regeneron’s hearing loss gene therapy Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer CRISPR Base Editing Repairs Hard-to-Treat Cystic Fibrosis Mutation in Cell Models FDA approves Regeneron’s hearing loss gene therapy Otarmeni Japanese Pharma Companies Turning to CDMOs Earlier in Product Life Cycle Substance use disorder biotech Tempero to close after earlier ‘serious’ safety event Heart’s beat may help it beat cancer, mouse research suggests Novartis’ radioligand therapy Lutathera could soon face generic competition FDA approval of Regeneron’s hearing loss gene therapy breaks barriers Regenerative Medicine: Promise, Hype, and What Actually Works Drugmaker AbbVie chooses North Carolina for $1.4B manufacturing campus AACR 2026 Video Update: Cancer Research Edges Toward an AI-Driven Era Amneal inks $1.1B Kashiv buyout to pursue biosimilar market leadership Opinion: Dropping the flu vaccine requirement puts U.S. military readiness at risk STAT+: CMS, FDA team up to fast-track reimbursement for breakthrough devices David Reese to retire from Amgen Regeneron ushers in new genetic medicine era with groundbreaking gene therapy approval Novel KIR‑CAR T Approach Shows Early Activity Against Solid Tumors BBOT shakes up leadership as RAS competitors get more visibility The next generation of cancer therapies revealed at AACR 2026 Novo’s pill for kids; Altimmune’s $225M offering; Merck teams with Google Cloud Sanofi defends Dupixent patents, but execs insist it has nothing to do with CEO change STAT+: AMA calls for regulatory crackdown on chatbots, wellness AI Endpoints wins Neal Awards for Trump and gene editing coverage, JPM event Across 7 hearings, RFK Jr. talks a new, more moderate MAHA Unnamed pharma files citizen petition targeting FDA’s trove of rejection letters Roche insists amylin obesity drug still valuable for patients who ‘don’t want side effects’ AAN 2026: J&J, Kyverna, Capricor and Praxis showcase practice-changing data Gravity Rail raises $2.75M from Redesign Health for AI patient communication AbbVie commits $1.4B to NC plant in its largest-ever single campus investment